Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDH305 with Standard of Care in IDH1 Mutant AML
NCT02826642Phase 1Withdrawn
- Sponsor
- Novartis
- Start
- Aug 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of idh305 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) (2 arms), sponsored by Novartis. Primary endpoints: Dose Limiting toxicities at 10 months and Adverse Events at 36 months. Planned start Aug 2016; status: withdrawn.
02
Drugs
idh305
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT02826642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02826642.